Capricor Therapeutics Inc represents values of innovation, patient-centric focus, and commitment to improving lives through transformative therapies. As a leading biotechnology company, Capricor is dedicated to developing and commercializing novel therapies for the treatment of life-threatening diseases. With a strong emphasis on research and development, Capricor strives to leverage cutting-edge science and technologies to address unmet medical needs. The company is driven by a corporate philosophy that emphasizes scientific integrity, collaboration, and delivering value to shareholders, healthcare professionals, and patients alike. Through its innovative approach, Capricor Therapeutics Inc aims to make a meaningful impact on the lives of patients and contribute to the advancement of healthcare.

Capricor Therapeutics Inc is primarily present in the United States.

Capricor Therapeutics Inc, a renowned biotechnology company, has achieved several significant milestones. Notably, the company successfully completed a Phase II clinical trial for its lead investigational therapy, CAP-1002, in patients with Duchenne muscular dystrophy (DMD). Additionally, Capricor Therapeutics Inc received a Rare Pediatric Disease Designation from the U.S. FDA for CAP-1002, further highlighting its potential in treating DMD. The company has also made progress in developing exosome-based therapies, demonstrating promising results in preclinical studies. Furthermore, Capricor Therapeutics Inc has secured valuable partnerships and collaborations to support its research and development initiatives, positioning itself as a key player in the field of regenerative medicine.

Capricor Therapeutics Inc is a biotechnology company headquartered in Los Angeles, California. Founded in 2005, Capricor is dedicated to the discovery, development, and commercialization of novel therapeutics for the treatment of rare diseases, particularly those affecting the cardiovascular system. The company focuses on developing regenerative medicine therapies utilizing its innovative platform technology, Cardiosphere-Derived Cells (CDCs). Capricor Therapeutics has been at the forefront of pioneering research in this field, aiming to provide effective and safe solutions for patients in need. With its commitment to advancing medical advancements, Capricor Therapeutics continues to make significant contributions to the biotech industry and patient care.

The main competitors of Capricor Therapeutics Inc in the market are companies such as Mesoblast Ltd, Pluristem Therapeutics Inc, and Athersys Inc.

Capricor Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Capricor Therapeutics Inc is focused on developing novel therapeutics for the treatment of various diseases. Capricor leverages its proprietary technology platform to develop innovative treatments targeting cardiac and other disorders. Through its research and development efforts, the company aims to address unmet medical needs by advancing its pipeline of potential therapies. Capricor Therapeutics Inc strives to create value for patients, healthcare providers, and investors by translating scientific discoveries into commercially viable products that have the potential to improve patients' quality of life.

Capricor Therapeutics KGV ir -3,00.

Capricor Therapeutics KUV ir 6,99.

AlleAktien kvalitātes vērtējums Capricor Therapeutics ir 4/10.

gaidāmā Capricor Therapeutics apgrozījums ir 19,13 milj. USD.

gaidāmā Capricor Therapeutics peļņa ir -44,48 milj. USD.

Capricor Therapeutics Inc is a biopharmaceutical company that focuses on the development, manufacturing, and commercialization of novel regenerative therapies for patients with cardiovascular diseases and other severe conditions. The company's business model is based on the discovery and development of groundbreaking technologies that are based on the latest scientific advancements and have the potential to fundamentally change patients' lives. The core business of Capricor Therapeutics Inc is the research, development, and commercialization of exosome vesicles, called EVs, as a new class of regenerative therapies. These small vesicles released by cells are important carriers of signaling and therapeutic agents in cell communication and have the potential to support tissue and organ regeneration and repair. Capricor's EV therapy platform is capable of isolating specific EV subtypes and their contents and producing them in a controlled and standardized environment. The company utilizes this technology to develop novel EV-based therapies for a variety of applications, including cardiovascular diseases, inflammatory diseases, and cancer. An example of a product based on Capricor's EV platform is currently a cell-free therapy for heart attack patients called CAP-1002. This therapy is derived from the patient's own adipose tissue and contains specific EV subtypes and other cellular components that can support the regeneration and repair of damaged heart tissue. Capricor Therapeutics Inc also pursues an innovative clinical strategy based on using EVs as biomarkers for disease prognosis and therapy monitoring. By analyzing specific EV subtypes and their contents in body fluids such as blood and urine, disease symptoms, disease progression, and therapy response can be better understood. The company also has a strategic partnership with Janssen Biotech, a subsidiary of Johnson & Johnson, for the development of EV-based therapies for severe inflammatory diseases such as inflammatory bowel disease (IBD) and other chronic conditions. Overall, Capricor Therapeutics Inc follows a diversified and innovative business model based on a robust EV platform and a strong clinical strategy. By developing novel regenerative therapies and utilizing biomarkers and diagnostics, the company has the potential to improve the lives of millions of patients around the world.

Capricor Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Capricor Therapeutics vai uzņēmums nedod dividendes.

Capricor Therapeutics ISIN ir US14070B3096.

Capricor Therapeutics WKN ir A2PLU4.

Capricor Therapeutics simbols ir CAPR.

Pēdējo 12 mēnešu laikā Capricor Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Capricor Therapeutics plāno maksāt dividendes 0 USD apmērā.

Capricor Therapeutics pašreizējā dividendu rentabilitāte ir .

Capricor Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Capricor Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Capricor Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Capricor Therapeutics apmērā 0 USD, kas tika izmaksāta 20.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 20.09.2024..

Pēdējās dividendes izmaksa notika 20.09.2024..

Gadā 2023, Capricor Therapeutics izmaksāja 0 USD dividendes.

Capricor Therapeutics dividendes tiek izmaksātas USD.